[go: up one dir, main page]

SMT202400105T1 - Metodi per trattare il cancro ovarico - Google Patents

Metodi per trattare il cancro ovarico

Info

Publication number
SMT202400105T1
SMT202400105T1 SM20240105T SMT202400105T SMT202400105T1 SM T202400105 T1 SMT202400105 T1 SM T202400105T1 SM 20240105 T SM20240105 T SM 20240105T SM T202400105 T SMT202400105 T SM T202400105T SM T202400105 T1 SMT202400105 T1 SM T202400105T1
Authority
SM
San Marino
Prior art keywords
methods
ovarian cancer
treating ovarian
treating
cancer
Prior art date
Application number
SM20240105T
Other languages
English (en)
Inventor
Mary Lynne Hedley
Robert Martell
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202400105(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of SMT202400105T1 publication Critical patent/SMT202400105T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SM20240105T 2016-06-29 2017-06-29 Metodi per trattare il cancro ovarico SMT202400105T1 (it)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662356461P 2016-06-29 2016-06-29
US201662402427P 2016-09-30 2016-09-30
US201762470141P 2017-03-10 2017-03-10
EP17821262.7A EP3478286B1 (en) 2016-06-29 2017-06-29 Methods of treating ovarian cancer
PCT/US2017/040039 WO2018005818A1 (en) 2016-06-29 2017-06-29 Methods of treating ovarian cancer

Publications (1)

Publication Number Publication Date
SMT202400105T1 true SMT202400105T1 (it) 2024-05-14

Family

ID=60787744

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20240105T SMT202400105T1 (it) 2016-06-29 2017-06-29 Metodi per trattare il cancro ovarico

Country Status (24)

Country Link
US (5) US20180311224A1 (it)
EP (2) EP3478286B1 (it)
JP (2) JP7083760B2 (it)
KR (2) KR102510996B1 (it)
CN (1) CN109640992A (it)
AU (1) AU2017290244B2 (it)
BR (1) BR112018077492A2 (it)
CA (1) CA3029671C (it)
DK (1) DK3478286T3 (it)
ES (1) ES2969816T3 (it)
FI (1) FI3478286T3 (it)
HR (1) HRP20240136T1 (it)
HU (1) HUE064978T2 (it)
IL (1) IL263925B2 (it)
LT (1) LT3478286T (it)
MX (1) MX394062B (it)
NZ (1) NZ749413A (it)
PL (1) PL3478286T3 (it)
PT (1) PT3478286T (it)
RS (1) RS65180B1 (it)
SG (1) SG11201811564QA (it)
SI (1) SI3478286T1 (it)
SM (1) SMT202400105T1 (it)
WO (1) WO2018005818A1 (it)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019008861A2 (pt) 2016-11-01 2019-07-09 Anaptysbio Inc anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
EP3534950A4 (en) 2016-11-01 2020-05-06 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
FI3565844T3 (fi) 2017-01-09 2023-05-09 Tesaro Inc Menetelmiä syövän hoitamiseksi anti-pd-1 -vasta-aineilla
SG10201913083SA (en) 2017-01-09 2020-03-30 Tesaro Inc Methods of treating cancer with anti-tim-3 antibodies
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
CN110753684A (zh) 2017-04-24 2020-02-04 特沙诺有限公司 尼拉帕利的制造方法
US12156872B2 (en) * 2017-05-09 2024-12-03 Tesaro, Inc. Combination therapies for treating cancer
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
KR20250016494A (ko) 2017-09-26 2025-02-03 테사로, 인코포레이티드 니라파립 제제
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
MA50618A (fr) 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations
RU2020129236A (ru) * 2018-02-05 2022-03-09 Тесаро, Инк. Педиатрические препараты нирапариба и способы лечения в педиатрии
WO2019195443A1 (en) * 2018-04-04 2019-10-10 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
KR20210071022A (ko) 2018-10-03 2021-06-15 테사로, 인코포레이티드 니라파립 염
US11640859B2 (en) 2018-10-17 2023-05-02 Tempus Labs, Inc. Data based cancer research and treatment systems and methods
US10395772B1 (en) 2018-10-17 2019-08-27 Tempus Labs Mobile supplementation, extraction, and analysis of health records
WO2020142583A1 (en) * 2019-01-04 2020-07-09 Actinium Pharmaceuticals, Inc. Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
US11705226B2 (en) 2019-09-19 2023-07-18 Tempus Labs, Inc. Data based cancer research and treatment systems and methods
TW202116316A (zh) * 2019-07-15 2021-05-01 美商提薩羅有限公司 治療卵巢、輸卵管及腹膜癌之方法
EP4018282A4 (en) * 2019-08-22 2023-08-16 Tempus Labs, Inc. UNSUPERVISED LEARNING AND PREDICTION OF THERAPY LINES FROM HIGH DIMENSIONAL LONGITUDINAL MEDICATION DATA
AU2020417223A1 (en) * 2019-12-31 2022-07-14 Kinnate Biopharma Inc. Treatment of cancer with CDK12/13 inhibitors
JP2023510853A (ja) * 2020-01-13 2023-03-15 グラダリス,インコーポレイティド Gm-csfをコードするポリヌクレオチドと追加薬剤を用いてがんを治療する方法
CN116490776A (zh) * 2020-10-29 2023-07-25 德州大学系统董事会 用于检测和治疗卵巢癌的方法
KR20230114557A (ko) 2022-01-25 2023-08-01 서울대학교산학협력단 상동 재조합 결핍 연관 유전자 도출 장치 및 방법, 상동 재조합 결핍 판단 모델 생성 장치 및 방법과, 상동 재조합 결핍 판단 장치 및 방법
EP4479050A1 (en) 2022-02-15 2024-12-25 Tesaro, Inc. Use of niraparib for the treatment of brain cancer
CN115253066A (zh) * 2022-07-21 2022-11-01 湖南安泰康成生物科技有限公司 卵巢癌治疗系统以及卵巢癌治疗的交变电场发生装置
CN116092631A (zh) * 2023-01-17 2023-05-09 湖南安泰康成生物科技有限公司 铁死亡诱导剂与电场联用的肿瘤治疗系统
WO2025061057A1 (en) * 2023-09-19 2025-03-27 Impact Therapeutics (Shanghai) , Inc Use of a parp inhibitor in maintenance therapy of ovarian cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
US20090123419A1 (en) * 2007-11-12 2009-05-14 Bipar Sciences Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
CA2711491C (en) 2008-01-08 2016-03-08 Jennifer R. Foley Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
WO2011160063A2 (en) 2010-06-18 2011-12-22 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
NZ606725A (en) 2010-08-24 2014-06-27 Dana Farber Cancer Inst Inc Methods for predicting anti-cancer response
WO2014052550A1 (en) * 2012-09-27 2014-04-03 Thomas Jefferson University Use of parp inhibitors to treat breast cancer
AU2014248007B2 (en) * 2013-04-05 2020-03-26 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
JP6663350B2 (ja) * 2014-01-16 2020-03-11 クロヴィス・オンコロジー,インコーポレーテッド ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのparp阻害剤の使用
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
US20150344968A1 (en) * 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
CN105384695B (zh) * 2014-08-22 2019-12-20 四川海思科制药有限公司 嘧啶衍生物及其制备方法和在医药上的应用
MX2018010223A (es) * 2016-02-29 2018-11-09 Synta Pharmaceuticals Corp Terapia combinada para tratamiento de cancer de ovario.

Also Published As

Publication number Publication date
US20240058319A1 (en) 2024-02-22
KR20230042136A (ko) 2023-03-27
JP7083760B2 (ja) 2022-06-13
US20180311224A1 (en) 2018-11-01
RS65180B1 (sr) 2024-03-29
WO2018005818A1 (en) 2018-01-04
US20220175752A1 (en) 2022-06-09
IL263925B2 (en) 2023-12-01
JP2019524690A (ja) 2019-09-05
DK3478286T3 (da) 2024-01-29
SG11201811564QA (en) 2019-01-30
JP2022031478A (ja) 2022-02-18
PT3478286T (pt) 2024-01-31
IL263925B1 (en) 2023-08-01
KR102510996B1 (ko) 2023-03-16
EP3478286B1 (en) 2024-01-03
HUE064978T2 (hu) 2024-04-28
EP4302835A2 (en) 2024-01-10
SI3478286T1 (sl) 2024-03-29
EP3478286A4 (en) 2020-03-18
PL3478286T3 (pl) 2024-04-22
ES2969816T3 (es) 2024-05-22
CA3029671C (en) 2023-08-15
IL263925A (en) 2019-01-31
LT3478286T (lt) 2024-04-25
CA3029671A1 (en) 2018-01-04
EP4302835A3 (en) 2024-03-20
KR20190029618A (ko) 2019-03-20
HRP20240136T1 (hr) 2024-04-12
BR112018077492A2 (pt) 2019-04-09
CN109640992A (zh) 2019-04-16
US20220395493A1 (en) 2022-12-15
AU2017290244B2 (en) 2023-03-02
MX2018016193A (es) 2019-06-10
EP3478286A1 (en) 2019-05-08
MX394062B (es) 2025-03-19
FI3478286T3 (fi) 2024-03-14
NZ749413A (en) 2023-05-26
US20220175751A1 (en) 2022-06-09
AU2017290244A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
IL263925A (en) Methods of treating ovarian cancer
IL275663A (en) Cancer treatment methods
ZA201804227B (en) Methods of treating cancer
IL255148A0 (en) Cancer treatment methods
SG10202110594UA (en) Methods of treating tumor
IL255569A (en) Methods of treating cancer using anti-ox40 antibodies
IL262342A (en) Cancer treatment methods
PT3490560T (pt) Niraparib para utilização num método de tratamento de cancro da próstata
IL261195B (en) Combined treatment for ovarian cancer
ZA201808258B (en) Methods of treating pancreatic cancer
ZA201802481B (en) Novel biomarkers and methods of treating cancer
IL263835A (en) Exosome-guided treatment of cancer
IL271934A (en) Methods for treating tumor metastases
EP3487999A4 (en) METHODS OF TREATING CANCER
SG11202005163PA (en) Methods of treating cancer
IL272379B1 (en) Methods for treating cancer using SETDs inhibition
IL269123A (en) Methods of treating cancer
IL265537A (en) Methods of treating ovarian cancer
GB201510197D0 (en) Method of treating ovarian cancer
HK40113232A (en) Methods of treating ovarian cancer
HK40098135A (en) Methods of treating ovarian cancer
HK40006340A (en) Methods for treating ovarian cancer
HK1263152A1 (en) Methods of treating cancer
GB201622214D0 (en) treatment of cancer
GB201604621D0 (en) Treatment of cancer